Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Thanatin TFA | 99.7% | 2433.92 (free base) | 5 MG
Thanatin TFA is an inducible cationic antimicrobial peptide (AMP) with a single-disulfide-bond-containing β-hairpin structure. It exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria, as well as various fungal species. This peptide functions by competitively replacing divalent cations from the bacterial outer membrane, leading to its disruption.
- Exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria.
- Effective against various species of fungi.
- Disrupts bacterial outer membrane.
- Potent inhibitory effect on NDM-1-producing E. coli and K. pneumoniae strains.
- Increases survival rates and decreases bacterial titers in infected mice.
- Rescues pathological damages in a dose-dependent manner in vivo.
Medchemexpress LLC HDAC11-IN-1 TFA | 99.3% | 995.15 | 1 MG
HDAC11-IN-1 TFA is a selective macrocyclic inhibitor of HDAC11 with a Ki of 40 nM. It exhibits good cell permeability and can inhibit the expression of YAP1 and SOX2. The product is for research purposes only and is not sold to patients.
- Selective macrocyclic inhibitor of HDAC11 with a Ki of 40 nM.
- Exhibits good cell permeability.
- Can inhibit the expression of YAP1 and SOX2.
- For research purposes only.
Medchemexpress LLC WP9QY TFA | 99.4% | 1340.40 | 1 MG
WP9QY, a TNF-a Antagonist, is a biologically active peptide.
- This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I.
- It prevents interactions of TNF with its receptor.
- This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.
Medchemexpress LLC CCZ01048 TFA | 98.5% | 1622.75 | 5 MG
CCZ01048 TFA is an α-MSH analogue that exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. It shows rapid internalization into B16F10 melanoma cells and demonstrates high in vivo stability, making it a promising candidate for PET imaging of malignant melanoma.
- α-MSH analogue
- High binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM
- Rapid internalization into B16F10 melanoma cells
- High in vivo stability
- Promising candidate for PET imaging of malignant melanoma
Medchemexpress LLC SAH-SOS1A TFA | 2896737-31-6 | 96.6% | 2301.55 | 1 MG
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. It binds to wild-type and mutant KRAS with nanomolar affinity, directly and independently blocking nucleotide association. This compound impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
- Peptide-based SOS1/KRAS protein interaction inhibitor
- Binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, Q61H) with nanomolar affinity (EC50=106-175 nM)
- Directly and independently blocks nucleotide association
- Impairs cancer cell viability
- Blocks ERK-MAPK phosphosignaling cascade downstream of KRAS
Medchemexpress LLC Wp9qy Tfa | 99.4% | 1340.40 | 5 MG
WP9QY TFA is a biologically active cyclic peptide designed as a TNF-α antagonist. It mimics the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, thereby preventing interactions of TNF with its receptor. This makes it a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.
- Acts as a TNF-α antagonist
- Designed to mimic TNF recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful for developing inhibitors for inflammatory bone destruction
- Helps prevent systemic bone loss in rheumatoid arthritis
Medchemexpress LLC Huwentoxin-IV TFA | 105856-78-4 | 99.04% | 4099.71 | 5 MG
Huwentoxin-IV TFA is a highly potent and selective blocker of neuronal voltage-gated sodium channels. It specifically inhibits NaV1.7 activity in human DRG neurons.
- Potent and selective sodium channel blocker
- Inhibits neuronal NaV1.7, NaV1.2, NaV1.3, and NaV1.4 channels
- IC50 of 2.9 nM for inhibiting NaV1.7-mediated currents
- Reduces NaV1.7 current amplitude by 50% at 0.5 nM
Medchemexpress LLC LARLLT (TFA) | 99.9% | 799.88 | 5 MG
LARLLT (TFA) is an EGFR-binding peptide with potential for research into EGFR overexpressing cancers, including lung, ovarian, and colorectal cancer.
- EGFR-binding peptide
- Potential for research of EGFR overexpressing cancers
- Targets EGFR
- Involves JAK/STAT signaling and protein tyrosine kinase/RTK pathways
- Sequence: Leu-Ala-Arg-Leu-Leu-Thr
- Molecular weight of 799.88
- Purity of 99.9% (HPLC)
- Soluble in DMSO: 50 mg/mL
- Appears as a white to off-white solid
- Powder storage: -80°C for 2 years, -20°C for 1 year
- In solvent storage: -80°C for 6 months, -20°C for 1 month (sealed storage, away from moisture)
Medchemexpress LLC BRP TFA (BRINP2-related peptide) TFA | 1540.88 (free base) | 5 MG
BRP (BRINP2-related peptide) TFA is a peptide that exhibits anti-obesity activity by activating FOS. It functions independently of leptin, GLP-1 receptor, and melanocortin 4 receptor.
- Exhibits anti-obesity activity
- Activates FOS in the central nervous system
- Functions independently of leptin, GLP-1 receptor, and melanocortin 4 receptor
- Classified as a peptide and therapeutic peptide
- Related to metabolic disease research
- Acts as an AP-1 activator
Medchemexpress LLC c-Myc Peptide TFA | 2918768-02-0 | 99.97% | 1317.32 | 5 MG
c-Myc Peptide TFA is a synthetic peptide that corresponds to the C-terminal amino acids (410-419) of human c-myc protein. It is involved in the regulation of growth-related gene transcription.
- Synthetic peptide corresponding to C-terminal amino acids (410-419) of human c-myc protein.
- Regulates growth-related gene transcription.
- Plays a critical role in the growth of breast cancer cells in vitro.
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 (free base) | 500 UG
Clovibactin TFA is the TFA salt form of Clovibactin. It acts as an antibiotic against drug-resistant bacterial pathogens without detectable resistance, functioning by inhibiting cell wall synthesis, specifically targeting pyrophosphate of peptidoglycan precursors.
- Inhibits cell wall synthesis.
- Targets pyrophosphate of peptidoglycan precursors.
- Effective against Staphylococcus strains with MICs of 0.125-2 μg/mL.
- For research use only.
- Molecular weight: 903.08 (free base).
- Formula: C43H70N10O11.xC2HF3O2.
- Appearance: Solid, white to off-white.
- Solubility: DMSO: 100 mg/mL (Need ultrasonic).
Medchemexpress LLC LIH383 TFA | 2866266-58-0 | 99.8% | 997.22 | 5 MG
LIH383 TFA is a white to off-white solid that has been tested and complies with specifications, exhibiting a high purity of 99.83% by HPLC.
- Tested and complies with specifications
- High purity of 99.83% (HPLC)
- White to off-white solid appearance
- Store in sealed conditions away from moisture
- Powder stable for 2 years at -80°C or 1 year at -20°C
- In solvent, stable for 6 months at -80°C or 1 month at -20°C
Medchemexpress LLC Cpp12 (Tfa) | 98.69% | 1700.55 | 1 MG
CPP12 TFA is a small, amphiphilic, cyclic cell-penetrating peptide (CPP) in salt form. It binds directly to plasma membrane phospholipids, enters mammalian cells via endocytosis, and is then efficiently released from endosomes. It can be used for intracellular delivery of drugs and chemical probes.
- Small, amphiphilic, cyclic cell-penetrating peptide (CPP)
- Binds directly to plasma membrane phospholipids
- Enters mammalian cells via endocytosis
- Efficiently released from endosomes
- Can be used for intracellular delivery of drugs and chemical probes
Medchemexpress LLC Rsm3 Tfa | 98.8% | 3049.66 | 1 MG
This product is a stapled peptide that acts as an inhibitor of METTL3-METTL14, with a Kd of 3.10 μM. It has been shown to inhibit tumor growth and induce cell apoptosis, making it useful for cancer research.
- It is a stapled peptide.
- It is a METTL3-METTL14 inhibitor.
- It inhibits tumor growth.
- It induces cell apoptosis.
- It is suitable for cancer research.
Medchemexpress LLC Vh4127 TFA | 1034.35 (free base) | 1 MG
VH4127 TFA is a cyclic peptide that targets the low-density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. It specifically binds to the epidermal growth factor (EGF) homology domain of both rodent and human LDLR.
- Targets low density lipoprotein receptor (LDLR)
- Has a high binding affinity (KD of 18 nM) for human LDLR
- Binds specifically to the EGF homology domain of rodent and human LDLR
- Available in various quantities
- For research use only
- Information on solubility, in vivo dissolution, and related antibodies is also available